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T-cell receptors (TCRs) govern the specificity, efficacy, and cross-reactivity of CD8 T cells. Here, we studied
CD8 T-cell clonotypes from Mane-A*10 pigtail macaques responding to the simian immunodeficiency virus
(SIV) Gag KP9 epitope in a setting of vaccination and subsequent viral challenge. We observed a diverse TCR
repertoire after DNA, recombinant poxvirus, and live attenuated virus vaccination, with none of 59 vaccine-
induced KP9-specific TCRs being identical between macaques. The KP9-specific TCR repertoires remained
diverse after SIV or simian-human immunodeficiency virus challenge but, remarkably, exhibited substantially
different clonotypic compositions compared to the corresponding populations prechallenge. Within serial
samples from individual pigtail macaques, only a small subset (33.9%) of TCRs induced by vaccination were
maintained or expanded after challenge. Most (66.1%) of the TCRs induced by vaccination were not detectable
after challenge. Our results suggest that some CD8 T cells induced by vaccination are more efficient than
others at responding to a viral challenge. These findings have implications for future AIDS virus vaccine
studies, which should consider the “fitness” of vaccine-induced T cells in order to generate robust responses
in the face of virus exposure.
The specificities of  T-cell receptors (TCRs) influence
both immunodominance and the emergence of viral escape
mutants in simian immunodeficiency virus (SIV)-infected rhe-
sus macaques (29) and human immunodeficiency virus (HIV)-
infected people (10, 22, 27, 42, 43). It is generally thought that
broad TCR repertoires are advantageous, since they have an
increased potential to recognize emerging viral escape variants
(6, 11, 29). However, structural features of the bound epitope
are a key determinant of repertoire selection (36) and thus the
scope for altering clonotype recruitment in response to defined
antigens by vaccination might be limited.
 TCRs are composed of two chains bearing membrane-
proximal constant regions and variable regions that govern
the interaction with major histocompatibility complex
(MHC)-bound peptide antigen. The  and  chain comple-
mentarity-determining regions (CDRs) are critical for me-
diating contact between the TCR and peptide/MHC com-
plex (17). In particular, the somatically recombined and
highly variable CDR3 loops form the primary contact with
the bound epitope (17). Studying CDR3 regions along with
V or V gene usage therefore provides substantial insight
into the clonal architecture of a particular response. Molec-
ular advances in the field of TCR repertoire analysis have
enabled such detailed studies through the quantitative ampli-
fication and characterization of rearranged expressed TRB
(and TRA) genes without bias (11, 29).
To date, studies of macaque TCRs expressed in SIV-derived
epitope-specific CD8 T-cell populations have been limited to
rhesus macaque models (18, 27, 33). Further, data that inform
on the evolution of TCR usage between vaccination and sub-
sequent viral exposure are even more limited. This is a critical
issue because the induction of specific T cells that most effec-
tively control viral replication is a key goal of T-cell-based
vaccination. A recent study of V usage in rhesus macaques
after vaccination and SHIV89.6 challenge showed that a focus-
ing of V usage occurred early after challenge (33). However,
how well this translates to CDR3 sequences after challenge,
and across other SIV models and macaque species, remains to
be determined.
Pigtail macaques that possess the Mane-A*10 MHC class I
allele develop an immunodominant response to the SIV
Gag164-172 KP9 epitope following both vaccination and SIV
or SHIV infection (9, 34). While the KP9-specific CD8 T-cell
response is beneficial in the setting of infection with wild-type
KP9 virus, viral escape occurs and abrogates the response (14).
The induction of an immunodominant KP9-specific response
in the setting of challenge with a virus already escaped at KP9
is counterproductive (13), presumably because it inhibits more
useful subdominant responses (15, 16). Here we studied the
TCR repertoire of KP9-specific CD8 T-cell populations in
pigtail macaques in order to understand the nature of this
important response at the molecular level.
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MATERIALS AND METHODS
Pigtail macaque samples. Eleven serial peripheral blood mononuclear cell
(PBMC) samples stored in liquid nitrogen from five Mane-A*10 pigtail
macaques involved in previously published vaccine studies were studied as shown in
Fig. 1a. Our institutional animal ethics committees approved all of our animal
studies. All five macaques were juvenile, with similar ages of 3 to 4 years. Both
animals in a study involving a recombinant vaccinia virus prime/recombinant
fowlpox virus boost coexpressing the immunomodulatory molecule 4-1BBL (VV/
FPV) followed by a SIVmac251 challenge were studied (32). We also studied two
Mane-A*10 animals that were involved in a DNA prime/recombinant fowlpox
virus boost (DNA/FPV) vaccine study and challenged with SHIVmn229 (9). These
two animals were selected from the four Mane-A*10 animals receiving the same
DNA/FPV vaccines based on high numbers of frozen PBMC available for study.
The one Mane-A*10 animal that received a live attenuated SIVmac239 strain
with nef and the long terminal repeat deleted in a previous study was also
analyzed for comparison (20). All vaccines expressed the wild-type KP9 epitope
within SIV Gag. The DNA/FPV study vaccine strain also expressed SIV Pol and
HIV type 1 AE subtypes Env, Tat, and Rev; the VV/FPV study vaccine strain
also expressed SIV Pol (9, 32).
Sequencing of the pigtail macaque TRBC locus. The constant region of the
pigtail macaque TCR  chain (TRBC) was sequenced with primers based on an
alignment of human and rhesus macaque TRBC sequences. Primers were di-
rected to regions on either side of the binding site for the TRBC primer previ-
ously described for the unbiased analysis of expressed rhesus macaque TRB
genes (11, 29). Pigtail macaque cDNA was amplified by PCR with the TCRB-
CFwd2 (GAG GAC CTG AAA AAG GTG TTC) and TCRB-CRev (CAT AGA
GGA TGG TGG CAG ACA) primers in a reaction mixture that included 10 l
5 Phusion HF buffer (Finnzymes), 1 l 10 mM deoxynucleoside triphosphates
(dNTPs; Promega), and 1 U Phusion DNA polymerase (Finnzymes), generating
a 448-bp product. Cycling parameters were 98°C for 30 s; 35 cycles of 98°C for 5 s,
50°C for 1 s, and 72°C for 15 s; and then a final extension at 72°C for 5 min.
Amplicons were A tailed, ligated into the pGEM-T Easy vector (Promega)
according to the manufacturer’s protocol, and transformed into competent Esch-
erichia coli JM109. Plasmid DNA from six clones was sequenced in both direc-
tions with the M13 and M13 primers.
Sample preparation and cell sorting. Pigtail macaque PBMC samples (6 106
to 14  106 cells) were thawed rapidly in a 37°C water bath and resuspended in
11 ml RF-10 (RPMI medium supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin) containing 1 l
DNase. Cells were washed twice to remove all traces of dimethyl sulfoxide and
then stained with 2 l allophycocyanin-conjugated Mane-A*10/KP9 (1 g, a
saturating amount) tetramer for 15 min at 37°C. After a further wash in phos-
phate-buffered saline, cells were stained at 4°C for 30 min with a panel of surface
markers (anti-CD28–phycoerythrin, anti-CD45RA–fluorescein isothiocyanate,
anti-CD3–allophycocyanin-Cy7, and anti-CD8–quantum dot 655/705) plus 5 l
of the amine-reactive viability dye ViViD (Invitrogen) (28). Cells were then
washed in RF-10 plus DNase and resuspended in 500 l RF-10 plus DNase. We
have previously shown that the Mane-A*10/KP9 tetramer demonstrates excellent
separation of positive and negative cells and that this tetramer does not stain
CD8 T cells in Mane-A*10-positive animals not exposed to SIV Gag or in
Mane-A*10-negative animals (9, 13, 21, 32, 35). Recognition of KP9 is specific to
this 9-mer peptide and does not overlap other SIV Gag epitopes described to
date (14).
Sorting of viable, single, tetramer CD3 lymphocytes was performed with a
modified FACSAria (BD) under biosafety level 3 conditions. Up to 10,000
KP9-specific CD8 T cells were sorted into 1.5-ml tubes containing 150 to 250 l
FIG. 1. Samples and sorting strategy for TCR repertoire analysis. (a) Sorted KP9-specific CD8 T cells (indicated by dots) were derived from
two animals receiving VV/FPV vaccines (total, six samples; left panel) and two animals receiving DNA/FPV vaccines (total, four samples; right
panel). Vaccination time points are indicated by upward-pointing arrows, along with the vaccine modalities administered. Viral challenge is
indicated by a downward-pointing arrow. (b) Gating strategy used to sort KP9-specific CD8 T cells. Thawed pigtail macaque PBMC samples were
stained with CD3, CD8, KP9 tetramer, CD45RA, CD28, and ViVid viability dye. Viable single CD3 tetramer lymphocytes, and singlets were
sorted into RNAlater with a modified BD FACSAria under biosafety level 3 conditions and used for TCR repertoire analysis.
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RNAlater (Ambion). Cell samples were then centrifuged briefly and immediately
frozen at 80°C.
mRNA extraction and cDNA synthesis. Cell samples were thawed and then
pelleted out of RNAlater by centrifugation. mRNA was extracted with the
Oligotex Direct mRNA Mini Kit (Qiagen) by following the manufacturer’s pro-
tocol. cDNA synthesis was conducted with the 5 SMART RACE (rapid ampli-
fication of cDNA ends) cDNA amplification kit (Clontech). The RACE cDNA
reaction involved 3 to 5 l mRNA together with 1 l 10 M SMART IIA
oligonucleotide (Clontech) and 1 l 10 M 5CDS primer (Clontech) placed at
70°C for 1 min and then at 20°C for 1 min. A 2-l volume of 5 RT buffer
(Clontech), 1 l 20 mM dithiothreitol (Clontech), 1 l RNaseOUT (Invitrogen),
1 l 10 mM dNTPs (Invitrogen), and 200 U Superscript II RNase H reverse
transcriptase (Invitrogen) were then added, and the reaction mixture was placed
at 42°C for 2 h. The reverse transcription reaction was stopped by the addition
of 10 l Tricine buffer (Clontech), followed by incubation at 72°C for 7 min.
The cDNA was then either stored at 80°C or used immediately for the an-
chored PCR.
Anchored PCR for unbiased amplification of TRB gene products. Expressed
TRB gene products were amplified in a 50-l reaction mixture comprising 7 l 5
RACE cDNA, 5 l 10 PCR buffer (Clontech), 5 l 10 universal primer mix
(Clontech), 0.5 l 25 M MBC 2 primer (rhesus macaque TRBC specific; TGC
TTC TGA TGG CTC AAA CAC AGC GAC CT), 0.5 l 25 M piggy MBC 2
primer (pigtail macaque TRBC specific; TGC TTC TGA TGG CTC AAA CAC
AGC AAC CT), 1 l 10 mM dNTPs (Invitrogen), and 1 l AdvanTaq2 DNA
polymerase enzyme cocktail (Clontech). Controls without a template were set up
in parallel for each sample. Amplification conditions were as follows: 30 s at
95°C; 5 cycles of 95°C for 5 s and 72°C for 2 min; 5 cycles of 95°C for 5 s, 70°C
for 10 s, and 72°C for 2 min; and then 30 cycles of 95°C for 5 s, 68°C for 10 s, and
72°C for 2 min.
Purification, cloning, and sequencing of amplified TRB gene products. PCR
products were resolved on a 1% agarose Tris-acetate-EDTA gel, sized against a
100-bp DNA ladder (Fermentas), excised, and purified with a QIAquick gel
extraction kit (Qiagen) according to the manufacturer’s protocol. Purified prod-
ucts were then ligated into the pGEM-T Easy vector (Promega) by following the
manufacturer’s instructions. Ligation reaction mixtures were left to incubate at
4°C overnight and then transformed into DH5 MAX Efficiency competent E.
coli (Invitrogen) and plated onto LB–100 g/ml ampicillin plates prespread with
isopropyl--D-thiogalactopyranoside (IPTG; Sigma) and 5-bromo-4-chloro-3-in-
dolyl--D-galactopyranoside (X-Gal; Invitrogen). Ninety-six white (insert-con-
taining) colonies were selected from each sample for a further round of PCR
amplification and sequencing. Reaction mixtures were set up in a 96-well plate
containing 25 l PCR mix per well as follows: 2.5 l 10 HiFi buffer (Invitro-
gen), 1 l 50 mM MgSO4, 0.5 l 10 mM dNTPs (Invitrogen), 1 l each 5 M
M13 primer and M13 primer, and 0.7 U Platinum Taq DNA polymerase
(Invitrogen). Individual colonies were selected and dotted onto a fresh LB–100
g/ml ampicillin plate. PCR conditions were 94°C for 5 min, followed by 35
cycles of 94°C for 30 s, 57°C for 30 s, and 68°C for 3 min. A final 3-min 72°C step
completed the reaction. A 12.5-l volume of each sample was then diluted 1:1 in
nuclease-free water and sent for sequencing (Agencourt Bioscience Corpora-
tion).
Sequence analysis of amplified TRB gene products. Sequence analysis of
subcloned TRB gene products was conducted with Sequencher version 4.1.2
(Gene Codes Corporation). All 96 sequences from each sample were trimmed of
ambiguous bases to a maximum of 400 bp. The trimmed sequences were then
assembled by using the dirty-data algorithm, with a minimum match percentage
of 93% and a minimum overlap of 20%. Amino acid translations were then used
to identify sequence motifs defining the ends of the V (CASS) and J
(XFGXG) regions. Any sequences less than 200 bp in length were discarded, as were
any sequences with no discernible V or J regions and those with in-frame stop
codons upstream of the CASS and XFGXG motifs. V designations were based
on comparison of the pigtail macaque amino acid sequences with 54 human
TRBV amino acid sequences listed in IMGT, the international ImMunoGeneTics
information system (23), accessible at http://imgt.cines.fr/textes/IMGTrepertoire
/Proteins/protein/human/TRB/TRBV/Hu_TRBVallgenes.html; most designa-
tions were possible with just the 14 amino acids ending with the CA of the CASS
motif. Similarly, J designations were based on comparison of the pigtail ma-
caque amino acid sequences with 13 human TRBJ sequences from IMGT,
accessible at http://imgt.cines.fr/textes/IMGTrepertoire/Proteins/protein/human
/TRB/TRBJ/Hu_TRBJallgenes.html. In cases where there was no exact match,
the closest human V or J sequence was selected. Arden’s nomenclature is used
herein (1), with sequences converted from the IMGT nomenclature according to
the table accessible at http://imgt.cines.fr/textes/IMGTrepertoire/LocusGenes
/nomenclatures/human/TRB/TRBV/Hu_TRBVnom.html#3.
Comparison of antigen-specific CD8 T-cell repertoires. Appropriate measure-
ments of TCR repertoire diversity and similarity must account for differences in
sample size and the dominance hierarchy of clonotypes (39). Taking the smallest
sample size and repeatedly randomly drawing the same number of events from
the larger samples (without replacement) can account for different sample sizes
(39). These “selected” samples can then by analyzed, and the median result can
be compared to the same analysis of the smallest sample. Simpson’s diversity
index is appropriate for the analysis of TCR repertoire diversity (26, 39); it is
sensitive to dominant clonotypes and less sensitive to the number of clonotypes
present. The Morisita-Horn index, originally used in ecological studies, is appro-
priate for determining the similarity of paired TCR repertoire samples (19, 38).
Additionally, it is most sensitive to the clone sizes of the dominant clonotypes.
Alanine scan to assess recognition of mutated KP9 epitopes. Nine peptides
containing alanine substitutions across the KP9 epitope were custom ordered
(GL Biochem, Shanghai). The alanine residue at position 5 of the wild-type
epitope was replaced with a lysine. These mutated epitopes, along with previ-
ously described escape mutant peptides K165R (KRFGAEVVP) and P172S
(KKFGAEVVS) (14), were used to restimulate PBMC from Mane-A*10 ani-
mals known to respond to KP9 at various concentrations in a standard 6-h
gamma interferon (IFN-) intracellular cytokine staining assay as previously
described (8).
Nucleotide sequence accession numbers. The Macaca nemestrina TRBC se-
quences have been lodged with GenBank and assigned accession numbers
EU493254 and EU493255.
RESULTS
Repertoire studies of KP9-specific CD8 T cells in pigtail
macaques. TCR specificities have a significant bearing on the
efficacy of a CD8 T-cell response. We were interested in
assessing the modulation of TCR repertoires over time,
particularly between vaccination and infection. A total of 11
postvaccination and postchallenge PBMC samples from five
Mane-A*10 pigtail macaques were analyzed. Four macaques
received prime/boost vaccines (two animals received DNA/
FPV vaccines, and two received VV/FPV vaccines, all express-
ing wild-type SIV Gag), and one macaque received a live
attenuated SIV for comparison (9, 20, 32). The levels of KP9-
specific CD8 T cells during the course of prime/boost vaccina-
tions and viral challenge are shown in Fig. 1a.
Viable KP9-tetramer-positive cells were successfully sorted
from all thawed, uncultured PBMC samples as depicted in Fig.
1b. Sample profiles, including sort yields and the eventual
numbers of TCR clones analyzed, are provided in Table 1.
Yields of viable KP-specific CD8 T cells from prechallenge
samples were lower due to the reduced frequency of Kp9-
specific CD8 T-cell populations present at these times.
As TCR repertoire analysis of pigtail macaques had not
previously been performed, it was necessary to sequence a
segment of the TRB constant region to ensure successful,
unbiased PCR amplification of expressed TRB gene products
from the sorted cells. The rhesus and pigtail macaque se-
quences were more than 97% homologous. Two single-nucle-
otide substitutions were discovered in clones from both of two
pigtail macaques studied that were not seen in rhesus macaque
sequences. Significantly, one of these substitutions occurred
within the region targeted by the published rhesus macaque
TRBC primer (12, 29). Our TRBV studies were therefore
conducted with an additional primer specific for the pigtail
macaque variant. Eleven PBMC samples from five separate
pigtail macaques were studied, yielding a total of 818 viable
TRB sequences from 1,056 clones sequenced.
Analysis of KP9-specific TCRs in pigtail macaques. The
TCR sequences generated from the sorted KP9-specific CD8
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T-cell populations were analyzed by comparing their amino
acid sequences with human V and J sequences. In cases
where the homology was low, the closest match to human
sequences was applied. For a summary of the CDR3 se-
quences, V and J designations, and clonotype frequencies of
all of the KP9-specific populations studied, see Table S1 in the
supplemental material.
The most striking observation from this complex data set
was the lack of any clear TCR selection patterns across the
outbred Mane-A*10 macaques, either after vaccination or in
response to SIV or SHIV challenge. Multiple TCR clonotypes
within the KP9-specific population were found, displaying
highly variable V usage, CDR3 lengths, and J usage. Most
samples showed diverse clonotypic repertoires, except for the
prechallenge sample from animal 6276, in which only one KP9-
specific clonotype was detected (6276 clonotype 12). This re-
sult is likely due to the low number and frequency of tetramer
cells obtained from this sample. However, this clonotype (6276
clonotype 12) was the only clonotype found in more than one
animal; clonotype 41 from macaque 5821 (found only at the
acute postchallenge time point) was identical, even at the nu-
cleotide level (data not shown).
Evolution of KP9-specific clonotypes between vaccination
and challenge. One advantage of working with macaques com-
pared to murine studies is the ready availability of longitudinal
blood samples from the same animal. Over time, the KP9-
specific TCR repertoires in each animal altered dramatically.
The observed repertoire modulations can be loosely divided
into three categories: (i) clonotypes that were present at all of
the time points analyzed, both after vaccination and after chal-
lenge (relatively stable); (ii) clonotypes that were not detect-
able after vaccination but subsequently emerged after chal-
lenge (emerging); and (iii) clonotypes that were present after
vaccination but were subsequently lost after challenge (declin-
ing). Examples of such modulations are given in Fig. 2. Al-
though some of the “relatively stable” clonotypes maintained
fairly constant frequencies across time points (e.g., animal 5821
clonotype 30, which accounted for 29.6, 24.1, and 28% of the
clonotypes), others varied greatly in frequency (e.g., animal
5827 clonotype 50, which accounted for 1.5, 17.9, and 2.9% of
the clonotypes). Emerging clonotypes were not elicited by vac-
cination, appearing only at postchallenge time points (e.g.,
5827 clonotype 42, which accounted for 0, 4.8, and 2.9% of the
clonotypes). Although some emerging clonotypes came to rep-
resent a substantial proportion of the overall repertoire (e.g.,
5821 clonotype 24, which accounted for 0, 9.6, and 12% of the
clonotypes), the majority of the emerging clonotypes repre-
sented only a minor proportion of the repertoire (e.g., 5616
clonotype 3, which accounted for 0 and 1.3% of the clono-
types). Declining clonotypes were elicited by vaccination and
lost following viral challenge. Interestingly, some of the dom-
inant clonotypes elicited by vaccination (e.g., 5616 clonotype 9,
which accounted for 12 and 0% of the clonotypes) were lost
following viral challenge.
TCR V usage by KP9-specific CD8 T cells. Analysis of V
usage by KP9-specific clonotypes again highlighted the remark-
ably diverse and polyclonal nature of these populations (Fig.
3). The repertoire of VV/FPV-vaccinated animal 5821 was
dominated by V 6.8 (blue in Fig. 3); however, patterns of V
usage in the other vaccinated animals were not clear-cut. For
example, V 6.8 was present in the KP9-specific repertoires
from animals 5827, 5616, and 6276 but only dominated follow-
ing SHIV challenge in animal 6276. Similarly, V 13.3 (gold)
was prominent in the 5616 response prechallenge but V 19.1/
25.1 (pink) dominated postchallenge. An assessment of which
V genes were used across the whole cohort (Table 2) shows
that the repertoires in VV/FPV-vaccinated animals 5821 and
5827 comprised a greater range of V genes than those in the
other three animals, although all of the responses were highly
diverse. Interestingly, no single V gene was used in all five of
the animals studied.
Although the V/J pairing was diverse, with the same V
being paired with multiple J segments even within the same
animal, some pairing patterns were apparent. For example, V
TABLE 1. TCR repertoire analysis
Animal Vaccine, challenge virus (reference) Sample Time point(wk)
%
Tetramera
No. of
cellsb
TCR
clone no.c
5821 VV/FPV-4-1BBL, SIVmac251 (32) Prechallenge 5 0.47 237 81
Postchallenge acute 19.5 3.17 10,000 83
Postchallenge chronic 36 1.4 2,500 50
5827 VV/FPV-4-1BBL, SIVmac251 (32) Prechallenge 5 0.15 800 65
Postchallenge acute 19.5 4.15 5,000 84
Postchallenge chronic 36 1.7 5,000 70
5616 DNA/FPV, SHIVmn229 (9) Prechallenge 12 0.14 530 75
Postchallenge acute 25 24.19 5,000 79
6276 DNA/FPV, SHIVmn229 (9) Prechallenge 12 0.14 300 93
Postchallenge acute 25 26.91 10,000 75
M18 Live-attenuated SIV (20) Postchallenge acute 7 0.21 700 63
a The tetramer responses listed were measured in fresh whole blood at the original trial time points, except for the animal M18 sample response and the animal 5821
and 5827 postchallenge chronic sample responses, which were measured in thawed PBMC samples.
b Shown is the number of cells obtained by sorting and subsequently used for RNA extraction and TCR repertoire analysis.
c Ninety-six colonies were screened for each sample. The TCR clone number is the number of colonies that yielded viable TCR sequence and were therefore included
in the analysis.
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19.1/25.1 was found in the repertoires of four animals, M18,
5616, 5821, and 5827. While macaque M18 had only one V
19.1/25.1 clonotype and paired it with J 1.4, the other three
animals preferentially paired V 19.1/25.1 with J 1.2 (5616,
one clonotype; 5821, three of five clonotypes; 5827, five of six
clonotypes; see Table S1 in the supplemental material). Simi-
larly, V 6.8 was also detected in the repertoires of four ani-
mals, 5616, 6276, 5821, and 5827. In three of the four animals
(5616, 5821, and 5827), the dominant V 6.8 clonotypes paired
with J 2.3. In macaque 6276, however, the V 6.8 clonotypes,
which all emerged after challenge, used four different Js, 1.1,
1.2, 1.6, and 2.2.
TCR diversity analyses of KP9-specific T-cell populations.
The overall diversity of the KP9-specific TCR repertoires can
be approximated by comparing the number of clonotypes de-
tected at each time point for each animal, estimated as if all
samples were of the same size (Fig. 4a). The estimated number
of clonotypes detected at each time point was relatively similar
for animals 5821 and 5827, and clonotype numbers were
greater than those detected for DNA/FPV-vaccinated animals
5616 and 6276.
A more meaningful measurement of diversity, however, is
one that accounts for the different clone frequencies of the
clonotypes in each sample (see Table S1 in the supplemental
FIG. 2. KP9-specific TCR clonotype modulations over time. TCR clonotypes present in samples from individual animals could be divided into
three categories, (i) those that were present at all of the time points studied after vaccination and challenge (relatively stable), (ii) those not present
after vaccination that emerged after challenge (emerging), and (iii) those present after vaccination that were subsequently lost after challenge
(declining). Examples of clonotypes from each animal that fall into each of these three categories are illustrated here, with clonotype identities
indicated by the keys on the right. Other clonotypes are displayed as random shades of gray.
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material for clonotype frequencies). Simpson’s diversity index
is an appropriate measurement of diversity for analyzing TCR
repertoires, with 0 representing minimal diversity and 1 repre-
senting maximal diversity (39). Using this index, following sam-
ple size compensation, it is clear that VV/FPV-vaccinated an-
imals 5821 and 5827 exhibited a more diverse repertoire than
the DNA/FPV-vaccinated animals (Fig. 4b). The analysis of
the prechallenge sample from DNA/FPV-vaccinated animal
FIG. 3. TCRBV usage in KP9-specific CD8 T-cell populations. The KP9-specific response was characterized by diverse TCRBV gene usage. All of the
TCRBV genes detected are listed in accordance with the nomenclature of Arden et al. (1) for the closest matching human sequence after conversion from the
TCRBV sequences accessed in IMGT at http://imgt.cines.fr/textes/IMGTrepertoire/Proteins/protein/human/TRB/TRBV/Hu_TRBVallgenes.html.
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5616 is skewed, however, because only a single clonotype was
detected from a very small cell sample. Apart from this sample,
however, the repertoire diversities were relatively stable across
the time points studied. In particular, there was no clear nar-
rowing of TCR repertoires after challenge.
Another way of analyzing TCR repertoires is to ask how
much the repertoires change, or remain the same, over time.
The Morisita-Horn similarity index can be used to compare
paired samples once the sample sizes have been normalized. In
this index, 0 represents minimal similarity (and therefore max-
imal divergence) and 1 represents maximal similarity (and
therefore minimal divergence). This index was applied to the
KP9-specific repertoire samples from each animal, using
paired time points (Fig. 4c). The repertoires for the two VV
prime/FPV boost-vaccinated animals showed differing pat-
terns, with all of the 5821 samples being quite similar to each
other and the 5827 samples being quite dissimilar between
time points. In particular, the prechallenge repertoire in 5827
was quite different from the repertoires at either of the post-
challenge time points. The two postchallenge samples (acute
and chronic) were more similar, although not as similar as the
two postchallenge time points from 5821. The similarity be-
tween the prechallenge and postchallenge (acute) samples for
the two SHIV A/E animals was also quite low.
While only a small number of animals was studied, it appears
that the KP9-specific CD8 T-cell repertoire is highly diverse,
with, to date, very little sharing of identical TCRs between
individuals. It also appears that different vaccination regimens
and challenge viruses are likely to influence the repertoires
that subsequently develop.
Phenotype of KP9-specific CD8 T cells. Our findings of a
diverse TCR repertoire expressed by most KP9-specific CD8 T
cells suggested that there were likely phenotypic differences
FIG. 4. Analyses of TCR repertoire similarity and diversity. The
diversity of the TCR repertoire was assessed in three different ways, (a)
comparison of the number of clonotypes found in each animal at each
time point; (b) calculation of the Simpson diversity index for each
sample, a measurement of diversity that is sensitive to the presence of
dominant clonotypes (0 	 minimum diversity, 1 	 maximum diver-
sity); and (c) calculation of the Morisita-Horn similarity index, com-
paring the clonotypes present in paired samples. In panel c, each line
represents the similarity between the samples indicated on the x axis;
for example, the grey solid line at the bottom compares the prechal-
lenge and postchallenge chronic samples from macaque 5827 (0 	
minimum similarity, 1 	 maximum similarity).
TABLE 2. TCRBV gene usage across pigtail macaque KP9-specific
CD8 T cells
TCRBV
gene
Presence in animal:
M18 6276 5616 5821 5827
1.1 No No No Yes No
2.1 No No No Yes Yes
3.1 No No No Yes No
4.1 No No No No Yes
5.1 No No No No Yes
5.2 No No No No Yes
5.6 No No No No Yes
6.2 No No No No Yes
6.4 Yes No No Yes No
6.8 No Yes Yes Yes Yes
7.1 Yes Yes No Yes Yes
8.1 Yes No No Yes No
9.1 No No No No Yes
12.1 No No No No Yes
12.3 No No No Yes No
13.2 No No No No Yes
13.3 No No Yes Yes No
14.1 Yes No Yes Yes Yes
15.1 No Yes No Yes Yes
16.1 No Yes Yes No Yes
17.1 Yes No No No Yes
19.1 Yes Yes No Yes Yes
20.1 No No Yes No No
22.1 Yes No Yes Yes Yes
23.1 No No No No Yes
5.2/5.7 Yes No No No No
19.1/25.1 Yes No Yes Yes Yes
8.1/8.2 No No No Yes No
13.3/13.4 No No No No Yes
22.1/7.1 Yes No No No No
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within the KP9-specific CD8 T-cell population. The costimu-
latory and memory molecule CD28/CD45RA phenotypes for
each sample were therefore assessed in parallel in the tet-
ramer populations (Fig. 5). The phenotypic profiles of KP9-
specific CD8 T cells from the postchallenge VV/FPV trial
samples were consistent with those observed in fresh whole
blood, suggesting that future phenotypic studies could be per-
formed with sequential frozen samples. Notably, the pheno-
typic profiles of the prechallenge samples (1 week postboost)
from these two VV/FPV-vaccinated animals were quite differ-
ent, with a larger CD28-CD45RA (purple) population in
5821 and a larger CD28-CD45RA (red) population in 5827.
The DNA/FPV-vaccinated animals had a larger proportion of
CD28 cells prechallenge (green and yellow) than the VV/
FPV vaccinees, potentially owing to priming via DNA rather
than VV. Following an acute SHIVmn229 challenge, the phe-
notypic profiles of the KP9-specific CD8 T cells in both of the
DNA/FPV-vaccinated animals were strongly dominated by
CD28 populations (purple and red), contrasting with the
profiles seen during acute SIV infection of the VV/FPV ani-
mals. The 4-tropic SHIVmn229 challenge virus resulted in a
much more dramatic early loss of CD4 T cells than the R5-
tropic SIVmac251 challenge (5), potentially explaining the dra-
matic difference in phenotype early after infection. The KP9-
specific CD8 T cells from the live attenuated SIV vaccinee,
M18, showed a phenotypic profile remarkably similar to those
at the prechallenge time point in the DNA/FPV-vaccinated
animals.
Broad recognition of mutants by KP9-specific CD8 T cells.
We have previously shown that viral escape at the KP9 epitope
involves a lysine-to-arginine change at position 2 (K165R) or,
less commonly, a proline-to-serine change at position 9
(P172S) as the exclusive escape mutations selected (14). Given
that the TCR repertoire directed toward the KP9 epitope is so
diverse and the dominant escape mutations are so uniform, we
studied the KP9/Mane-A*10/TCR interaction by evaluating
which residues within the KP9 epitope are critical for T-cell
recognition. Peptides containing sequential alanine substitu-
tions across the KP9 epitope (except the position 5 alanine,
which was replaced with a lysine) were used at various con-
centrations in an IFN- intracellular cytokine assay and com-
pared to the wild-type KP9 epitope. Two separate assays with
different peptide concentrations were conducted with fresh
blood from two separate Mane-A*10 animals (Fig. 6).
We observed almost identical patterns of partial recognition
of KP9 mutants in the two separate titrations covering a large
dynamic range of peptide concentrations (Fig. 6). Alanine sub-
stitutions at positions 1, 2, and 4 are tolerated reasonably well.
Alanine mutations at positions 3, 6, and 7 of the KP9 epitope
abrogate most CD8 T-cell reactivity, as does the lysine mu-
tation at position 5. Alanine mutations at positions 8 and 9
reduce reactivity compared to the wild-type epitope. Common
escape mutant peptides K165R and P172S show limited reac-
tivity to both peptides at 100 ng/ml, although this drops to
background levels at 5 ng/ml. Since the TCR repertoires are
diverse, it is likely that this reactivity is restricted to a subset of
clonotypes within the overall repertoire.
DISCUSSION
In this study, we characterized the TCR repertoire of CD8
T-cell populations specific for the immunodominant Mane-
FIG. 5. CD45RA/CD28 phenotypes of sorted KP9-specific CD8 T cells. The CD45RA/CD28 phenotypes are shown for the KP9-specific CD8
T-cell populations sorted for TCR analysis from each of the 11 pigtail macaque PBMC samples. The two VV/FPV-vaccinated animals (5821, 5827)
were challenged with SIVmac251, and the two DNA/FPV-vaccinated animals (5616, 6276) were challenged with SHIVmn229. M18 was administered
live attenuated SIV (proviral SIVmac239 DNA with nef and long terminal repeat deletions) (20).
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A*10-restricted SIV Gag164-172 KP9 epitope in pigtail ma-
caques. TCR repertoires have not previously been investigated
in pigtail macaques, and it was necessary to sequence the TRB
constant region to ensure unbiased amplification (29). Several
single nucleotide substitutions were detected within the se-
quenced constant region, although only two of these substitu-
tions were present exclusively in pigtail macaque sequences.
Our pigtail macaque TRB amplifications therefore included
novel primers based on these sequences.
Several intriguing insights into the molecular characteristics
of KP9-specific CD8 T-cell populations emerged. Remarkably,
only 1 out of 161 different KP9-specific clonotypes was found in
more than one animal, suggesting that the KP9-specific re-
sponse is mediated by a diverse repertoire of clonotypes that
are highly “private” to individual animals in this outbred pop-
ulations. This contrasts with TCR repertoires dominated by
“public” or shared repertoires between individuals which occur
either when a particular TCR has a selection advantage over
others (2) or when unusual structural features limit the number
of reactive clonotypes (24). The selection of highly “private”
TCR repertoires suggests that the bound KP9 epitope presents
sufficient physical features to elicit recognition by multiple
clonotypes but does not have any unusual features that might
restrict recognition or give some clonotypes a selection advan-
tage over others (36). Our findings that there was significant
recognition of mutated KP9 variants and a diverse phenotype
of KP9-specific CD8 T cells are also consistent with the broad
TCR repertoire we identified. Future analyses of the TCR
repertoires of subpopulations of KP9-specific CD8 T cells with
different avidities (as identified by using lower concentrations
of the tetramer) are also suggested by these studies (30).
Despite the overall diversity of the KP9-specific repertoire,
some animals did demonstrate a bias toward the use of a
particular V gene within this response (for example, V 6.8 in
animal 5821). These patterns were not consistent across all of
the animals studied, however. Notably, the V bias was not
reflected in the CDR3 sequences, with multiple CDR3 se-
quences occurring in conjunction with individual V segments.
The CDR3 loops are likely to be more important in the spec-
ificity of antigen recognition than TRBV-encoded CDR1 and
FIG. 6. Recognition of KP9 mutants. Peptides containing sequential alanine mutations across the KP9 epitope were studied in IFN-
intracellular cytokine assays of whole blood from Mane-A*10 animals with KP9-specific CD8 T-cell responses. (a) Alanine scan titration of blood
from VV/FPV-immunized animal 5827. (b) Comparative reactivity of each alanine mutant with wild-type (WT) KP9 peptide at 100 ng/ml (from
the titration shown in panel a). (c) Additional alanine scan titration, including the common K165R and P172S mutations, of a separate blood
sample. (d) Comparative reactivity of each alanine mutant with the WT KP9 peptide at 100 ng/ml (from the titration shown in panel c). A1 	
AKFGAEVVP, A2 	 KAFGAEVVP, A3 	 KKAGAEVVP, A4 	 KKFAAEVVP, K5 	 KKFGKEVVP, A6 	 KKFGAAVVP, A7 	
KKFGAEAVP, A8 	 KKFGAEVAP, A9 	 KKFGAEVVA, K165R 	 KRFGAEVVP, and P172S 	 KKFGAEVVS (mutations are in bold).
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CDR2 (17). In this study, the CDR3 sequences did not show
any common features or motifs. CDR3 lengths were highly
variable, with an average of 14 amino acids, but the dominant
clonotypes, even within an individual macaque, contained
CDR3 loops of various lengths. Long TRB CDR3 sequences
have been associated with improved recognition of emerging
escape mutants and long-term viral control in HLA-B8 HIV-
infected humans (10). In the latter study, however, the CDR3
sequences were highly conserved between individuals and were
paired with common V and J segments; this is in marked
contrast to the KP9-specific repertoire.
In mice, study of a single TCR binding to the same MHC
molecule presenting two different peptides has shown that the
CDR3 loop is crucial for TCR cross-reactivity (31). This is
consistent with studies with SIV-infected Mamu-A*01 rhesus
macaques, where a restricted repertoire directed toward the
Tat TL8 epitope was associated with consistent patterns of
viral escape (29). It is therefore conceivable that the wide
repertoire of KP9-specific CD8 T cells in general, and the
diverse CDR3 lengths and sequences in particular, contributes
to the recognition of potential escape variants, therefore lim-
iting successful viral escape to mutations such as the dominant
K165R mutation (14). Such a mechanism appears to account
for the development of escape at the Gag CM9 epitope in
rhesus macaques (7, 29), although escape at CM9 generally
occurs much later than escape at the KP9 epitope (3, 4, 14).
Additionally, repertoire breadth resulting from multiple reac-
tive clonotypes within the naı¨ve T-cell repertoire appears to
contribute significantly to the immunodominance of the Gag
CM9 epitope (18) and may also account, at least in part, for the
immunodominance of the KP9 epitope.
The mechanistic basis for the availability of a large reper-
toire of potentially reactive clonotypes specific for the KP9
epitope may lie in the structural nature of the antigen. Manip-
ulations of a murine influenza virus epitope have elegantly
demonstrated the impact of epitope structural features on
TCR repertoire diversity (37). A diverse TCR repertoire di-
rected toward the wild-type H-2Db-restricted PA224 epitope
with a prominent central arginine residue was transformed into
a more uniform and less diverse repertoire when the arginine
residue was mutated to alanine (37). Thus, the highly diverse
KP9-specific repertoire suggests that the KP9 epitope com-
plexed to Mane-A*10 may have prominent structural features
that enable the selection of broad TCR specificities. Structural
studies of the KP9 epitope bound to Mane-A*10 would help to
profile the features that contribute to TCR repertoire diversity
in this case.
The initial studies described herein focused on serial sam-
ples from DNA/poxvirus-vaccinated macaques subsequently
challenge with SIV or SHIV. A common observation, regard-
less of the vaccination type or challenge virus, was the reten-
tion of only a small subset of vaccine-induced clonotypes after
challenge (stable TCRs in Fig. 2). Many clonotypes induced by
vaccination were not detectable after viral challenge, and many
new clonotypes, not detected prechallenge, appeared after
challenge. These observations could suggest that only a limited
number of KP9-specific clonotypes induced by vaccination can
expand and respond effectively to a viral challenge.
Our studies, using an unbiased TCR sequencing approach,
complement a recently reported study that used TRBV-spe-
cific primers to examine the SIV-specific repertoire in vacci-
nated rhesus macaques (33). In the latter study, diverse V
usage after prime/boost vaccination was also observed, al-
though a transient narrowing of V usage was detected early,
but not late, after SHIV89.6 challenge. In contrast to our stud-
ies, they found common CDR3 sequences within particular V
PCR products from SIV-specific cytotoxic T lymphocytes
present in several rhesus macaques. The differences may re-
flect, in part, the different methodologies used for repertoire
analysis but perhaps more likely reflect biological differences in
the nature of the antigenic epitopes targeted and the SIV/
macaque models used.
Understanding how to induce effective CD8 T cells that can
respond to challenge and limit immune escape is a key goal of
future T-cell-based vaccination strategies. A recent study has
shown that therapeutic vaccination can modulate CD8 T-cell
repertoires in HIV-infected individuals (40), although the
long-term impact of such manipulations on viral control has
not been evaluated. Investigating the preferred clonotypic
characteristics of effective CD8 T cells and how to elicit them
through prophylactic or therapeutic vaccination remains an
important field of enquiry. Single-cell cloning of CD8 T cells
may contribute to our understanding through in vitro studies of
clonal T-cell efficacy (25, 41). However, our data raise theo-
retical concerns about the representative nature of such ap-
proaches because individual antigen-specific clonotypes clearly
exhibit differential abilities to expand upon viral exposure and
hence presumably to assist in the control of viremia. Further-
more, such procedures can skew the biological properties of
individual CD8 T-cell clones, regardless of TCR expression.
Thus, detailed characterization of antigen-specific clonotypes
directly ex vivo will perhaps prove to be more informative.
The study presented here was limited by the modest number
of pigtail macaques studied at serial time points. Additionally,
although we attempted to clone nearly 100 separate TCRs at
each time point, we cannot be sure that we captured the entire
population of CD8 T-cell clonotypes, particularly in cases
where low numbers of KP9-specific CD8 T cells were present
in the samples (e.g., prechallenge in animal 6267). These sam-
pling issues are especially relevant to highly polyclonal popu-
lations, such as those specific for KP9 in animals 5821 and
5827. Further, although we observed a great degree of clono-
typic diversity, even within individual pigtail macaques on the
same vaccination/challenge protocol, studies of larger numbers
of animals receiving identical vaccines might reveal subtle pat-
terns that are not yet apparent. For example, the VV/FPV-
vaccinated animals had moderately higher numbers of clono-
types and exhibited greater clonotypic diversity compared to
DNA/FPV vaccinees (Fig. 4). This observation, which could
have several underlying mechanistic explanations, suggests that
different vaccine formulations can elicit different repertoires
specific for the same antigen. Thus, while the nature of the
antigen is likely the primary determinant of which clonotypes
can be recruited, the mode of delivery might dictate which
clonotypes are actually recruited; importantly, such differences
might translate into differential outcomes after challenge.
However, first and foremost, confirmation of these findings in
larger comparative studies is warranted. Another limitation of
this study is that we restricted our analysis to TCR  chains. To
confirm the overall diversity of the KP9-specific TCR reper-
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toire, studies should be extended to the TCR  chains that pair
with the TCR  chains described here (18). Such studies could
ultimately lead to a structural analysis of TCR engagement
with the KP9/Mane-A*10 complex and a more detailed under-
standing of the generation of TCR repertoire diversity and the
emergence of viral escape.
It is clear that the immunodominant Gag KP9-specific CD8
T-cell response is a key component of adaptive immunity dur-
ing vaccination and SIV or SHIV challenge in pigtail ma-
caques. In this study, we have begun to characterize the diverse
nature of this useful CD8 T-cell response at the clonotypic
level. These first insights into the substantial TCR repertoire
that can be mobilized in response to KP9 reveal the diversity of
CD8 T-cell populations that recognize this epitope and suggest
that, within this complexity, there might be multiple features
that contribute to biological outcome. Further detailed pheno-
typic and functional studies of antigen-specific clonotypes in
different vaccine/challenge models will, we hope, clarify the
central determinants of successful CD8 T-cell-mediated immu-
nity and potentially guide vaccine development.
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